| Perennial Income Generator Fund (Managed Fund) (EIGA) |
Financials |
$28 |
EIGA and IMPQ Monthly Units Release December
|
8 Jan 2025 9:21AM |
$3.830 |
$3.640 |
fallen by
4.96%
|
|
| Mitchell Services Limited (MSV) ORDINARY FULLY PAID |
Materials |
$71 |
Update - Notification of buy-back - MSV
|
8 Jan 2025 9:20AM |
$0.350 |
$0.335 |
fallen by
4.29%
|
|
| Highfield Resources Limited (HFR) ORDINARY FULLY PAID |
Materials |
$19 |
Notification of cessation of securities - HFR
|
8 Jan 2025 9:20AM |
$0.240 |
$0.041 |
fallen by
82.92%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$1,821 |
Application for quotation of securities - 4DX
|
8 Jan 2025 9:20AM |
$0.545 |
$3.510 |
risen by
544.04%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$162 |
Application for quotation of securities - VVA
|
8 Jan 2025 9:19AM |
$1.440 |
$1.645 |
risen by
14.24%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$29,385 |
EGM Shareholder Meeting Date
|
8 Jan 2025 9:18AM |
$15.240 |
$12.730 |
fallen by
16.47%
|
|
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$35 |
Update - Notification of buy-back - MEC
|
8 Jan 2025 9:18AM |
$1.040 |
$1.090 |
risen by
4.81%
|
|
| Opthea Limited (OPT) ORDINARY FULLY PAID |
Health Care |
$821 |
Opthea to Host Investor Days in New York and Australia
|
8 Jan 2025 9:18AM |
$0.795 |
$0.600 |
fallen by
24.53%
|
|
| Archer Materials Limited (AXE) ORDINARY FULLY PAID |
Information Technology |
$90 |
Breakthrough in Quantum Carbon Films for Qubit Realisation
|
8 Jan 2025 9:17AM |
$0.455 |
$0.355 |
fallen by
21.98%
|
|
AXE - Price-sensitive ASX Announcement
Full Release
Key Points
- Archer has improved the electron spin lifetime to 800 ns at room temperature.
- The improvement enhances manufacturability for quantum carbon films.
- Sample-to-sample repeatability has significantly increased.
- Testing on nanoscale islands of carbon films has begun.
- Collaborative work with Queen Mary University of London is ongoing.
- Further development with The École Polytechnique Fédérale de Lausanne aims at achieving spin readout.
- Archer continues to work towards practical qubit and sensor devices.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$313 |
Daily Stabilisation Activity Report - 7 January 2025
|
8 Jan 2025 9:17AM |
$8.630 |
$7.600 |
fallen by
11.94%
|
|
| iTech Minerals Ltd (ITM) ORDINARY FULLY PAID |
Materials |
$11 |
Cleansing Notice - Share Issue
|
8 Jan 2025 9:16AM |
$0.055 |
$0.044 |
fallen by
20%
|
|
| OD6 Metals Limited (OD6) ORDINARY FULLY PAID |
Materials |
$15 |
Geophysical and Geochemical Surveys Commenced at Gulf Creek
|
8 Jan 2025 9:16AM |
$0.050 |
$0.077 |
risen by
54%
|
|
OD6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Geophysical and geochemical surveys commenced at Gulf Creek Copper Project.
- The surveys aim to identify conductive massive sulphide material.
- Electromagnetic survey complements existing magnetic modelling.
- Geochemical soil sampling aims to identify anomalous elements.
- Surveys target old workings and extended areas.
- Phase 1 drilling is scheduled to commence this quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$91 |
Trading Halt
|
8 Jan 2025 9:14AM |
$0.175 |
$0.076 |
fallen by
56.57%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Arovella Therapeutics Limited requested a trading halt.
- The trading halt is effective from January 8, 2025.
- The halt is pending an announcement regarding a significant investment.
- The trading halt will last until January 10, 2025, or until the announcement is released.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$159 |
AVH Updates Expected Q4 & FY24 Revenue, FY25 Guidance
|
8 Jan 2025 9:13AM |
$4.350 |
$1.045 |
fallen by
75.98%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- AVITA Medical expects Q4 2024 revenue of approximately $18.4 million.
- Q4 revenue reflects a growth of around 30% compared to Q4 2023.
- Full-year 2024 revenue is now estimated at around $64.3 million.
- The revision in guidance is due to slower-than-expected purchasing activities.
- Company anticipates full-year 2025 revenue in the range of $100 to $106 million.
- This reflects a growth of approximately 55% to 65% over projected 2024 revenue.
- AVITA Medical aims for cash flow break-even and GAAP profitability by Q4 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Santana Minerals Limited (SMI) ORDINARY FULLY PAID |
Materials |
$705 |
RAS Drill Results Continue to Glow
|
8 Jan 2025 9:13AM |
$0.455 |
$0.845 |
risen by
85.71%
|
|
SMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Ongoing diamond drilling at Rise and Shine (RAS) deposit shows positive results.
- Drill hole MDD379 reported 16.4m at 5.7g/t Au and 7.0m at 21.7g/t Au.
- The drilling program aims to enhance operational readiness for a design phase in 2025.
- Results align with predictions of geological continuity, increasing confidence in the resource model.
- An updated Mineral Resource Estimate (MRE) is expected to be finalized in Q1 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titan Minerals Limited (TTM) ORDINARY FULLY PAID |
Materials |
$229 |
Dynasty Gold Project Activities Updates
|
8 Jan 2025 9:11AM |
$0.380 |
$0.800 |
risen by
110.53%
|
|
| iTech Minerals Ltd (ITM) ORDINARY FULLY PAID |
Materials |
$11 |
Application for quotation of securities - ITM
|
8 Jan 2025 9:11AM |
$0.055 |
$0.044 |
fallen by
20%
|
|
| Claremont Global Fund (Hedged) (Managed Fund) (CGHE) CLAREMONT GLOBAL FUND (HEDGED) ACTIVE ETF |
Financials |
$69 |
Units on Issue & Monthly Unit Movements - December 2024
|
8 Jan 2025 9:10AM |
$1.750 |
$1.725 |
fallen by
1.43%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$162 |
Update - Notification of buy-back - VVA
|
8 Jan 2025 9:07AM |
$1.440 |
$1.645 |
risen by
14.24%
|
|
| Claremont Global Fund (Managed Fund) (CGUN) CLAREMONT GLOBAL FUND ACTIVE ETF |
Financials |
$72 |
Units on Issue & Monthly Unit Movements - December 2024
|
8 Jan 2025 9:07AM |
$1.815 |
$1.590 |
fallen by
12.40%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$12,218 |
Statement of CDIs on issue - LNW
|
8 Jan 2025 9:05AM |
$137.670 |
$152.250 |
risen by
10.59%
|
|
| Franklin Global Growth Fund (Managed Fund) (FRGG) |
Financials |
$308 |
Applications, Redemptions, Units on Issue and OTC 31.12.2024
|
8 Jan 2025 9:05AM |
$2.620 |
$2.060 |
fallen by
21.37%
|
|
| Franklin Australian Absolute Return Bond Fund (Managed Fund) (FRAR) |
Financials |
$713 |
Applications, Redemptions, Units on Issue and OTC 31.12.2024
|
8 Jan 2025 9:05AM |
$1.015 |
$1.050 |
risen by
3.45%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$290 |
Third Consecutive Quarter of Record Revenue for Orthocell
|
8 Jan 2025 9:03AM |
$1.255 |
$1.070 |
fallen by
14.74%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell achieved a record revenue of $2.21 million in December 2024 Quarter.
- Revenue has increased by 9% from $2.03 million in the previous quarter.
- There is a 46% year-over-year growth compared to December 2023's revenue of $1.51 million.
- Products Striate+â„¢ and Remplirâ„¢ are sold in several international markets including the US, Canada, and Europe.
- FDA approval for Remplirâ„¢ is expected by March/April 2025, targeting the US nerve repair market.
- Orthocell has about $31 million in cash and expects an R&D rebate of approximately $3 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,553 |
Notification regarding unquoted securities - HLI
|
8 Jan 2025 9:03AM |
$4.540 |
$5.700 |
risen by
25.55%
|
|